At the end of the latest market close, Eli Lilly and Company (LLY) was valued at $147.42. In that particular session, Stock kicked-off at the price of $146.98 while reaching the peak value of $150.14 and lowest value recorded on the day was $146.91. The stock current value is $149.30.
Recently in News on December 8, 2020, Lilly Confirms Date and Conference Call for 2021 Financial Guidance Announcement. Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2021 on Tuesday, December 15, 2020. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial guidance. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Eli Lilly and Company had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $170.75 on 07/09/20, with the lowest value was $117.06 for the same time period, recorded on 03/23/20.
Eli Lilly and Company (LLY) full year performance was 24.17%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Eli Lilly and Company shares are logging -12.56% during the 52-week period from high price, and 27.54% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $117.06 and $170.75.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2753331 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Eli Lilly and Company (LLY) recorded performance in the market was 13.60%, having the revenues showcasing -1.76% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 138.64B, as it employees total of 33625 workers.
Market experts do have their say about Eli Lilly and Company (LLY)
During the last month, 10 analysts gave the Eli Lilly and Company a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 148.22, with a change in the price was noted -16.66. In a similar fashion, Eli Lilly and Company posted a movement of -10.04% for the period of last 100 days, recording 3,612,135 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for LLY is recording 3.51 at the time of this writing. In addition, long term Debt to Equity ratio is set at 3.38.
Technical breakdown of Eli Lilly and Company (LLY)
Raw Stochastic average of Eli Lilly and Company in the period of last 50 days is set at 71.90%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 92.71%. In the last 20 days, the company’s Stochastic %K was 89.61% and its Stochastic %D was recorded 77.98%.
Bearing in mind the latest performance of Eli Lilly and Company, several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 13.60%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -1.13%, alongside a boost of 24.17% for the period of the last 12 months. The shares increased approximately by 2.57% in the 7-day charts and went down by 4.60% in the period of the last 30 days. Common stock shares were lifted by -1.76% during last recorded quarter.